AltheaDx this week announced the launch of its Affymetrix Drug Metabolizing Enzymes & Transporter genotyping microarray service.
According to the company, the new service provides biopharmaceutical clients with "a way to measure the genetics of drug metabolism in clinical trial patients — giving drug developers the opportunity to select patients that are more likely to respond."
AltheaDx will compile patients' genetic data in a report for customers, and this information can then be integrated into existing clinical trial protocols.
"The DMET report includes biomarker analysis from all US Food and Drug Administration-validated genes and more than 150 well-documented biomarkers known to impact drug metabolism," the company said in a statement. "In addition to these proven biomarkers, the report contains information on a total of 1,936 genetic variants in 225 enzyme and transporter genes, making it a useful tool for exploratory pharmacokinetic studies to identify new biomarkers such as variants in CYP4F2, recently discovered using DMET to explain 8 percent of warfarin dosing variability."